Table 1.
Descriptive characteristics of the study groups (N = 29).
| iTAB (n = 20) | Control (n = 9) | |
|---|---|---|
| Demographics | ||
| Age; mean (SD) | 46.8 (8.3) | 52.4 (6.6) |
| Education; mean (SD) | 13.2 (2.7) | 14.3 (2.7) |
| Male; % (#) | 90.0% (18) | 100.0% (9) |
| Caucasian; % (#) | 55.0% (11) | 33.3% (3) |
| HIV disease characteristics | ||
| CD4 count; median [IQR]a | 586.5 [140.5, 974.8] | 606.5 [198.3, 1053.8] |
| Nadir CD4 count; median [IQR]b | 148 [14.8, 493.8] | 235 [153, 362.5] |
| HIV RNA plasma; median [IQR]c | 1.6 [1.6, 1.9] | 1.6 [1.6, 3.2] |
| RNA plasma detectable % (#)d | 26.3% (5) | 37.5% (3) |
| AIDS % (#)e | 50.0% (2) | 50.0% (2) |
| Time since first positive test; mean (SD)f | 125.5 (101.0) | 201.1 (104.9) |
| Meth use characteristics | ||
| Age of first use; mean (SD)g | 30.0 (12.0) | 29.2 (14.6) |
| Total days used; mean (SD) | 1634.8 (2190.8) | 1516.2 (1551.5) |
| Total quantity used; mean (SD)h | 1058.7 (1663.4) | 1593.4 (2396.4) |
Key: a n = 8, bNadir CD4 count is self-reported, n = 16; cin log copies/mL, n = 27; d<50 cp/mL, n = 27; eAIDS status based on the 1993 CDC classification scheme, n = 8; ftime since first positive test is calculated in months, n = 8; g n = 25, htotal quantity is in grams. Note: no significant differences were observed for any of the reported variables.